| Abstrakt: |
A recent study conducted at Anthea Hospital in Bari, Italy, examined the effects of Evolocumab treatment on dyslipidemic patients who underwent coronary artery bypass grafting (CABG) surgery. The researchers found that Evolocumab significantly reduced LDL cholesterol and total cholesterol levels compared to statin treatment alone. However, after one year of follow-up, this reduction did not have an impact on the reduction of major clinical events. The study concluded that Evolocumab is safe and effective in reducing cholesterol levels but may not have a significant effect on long-term clinical outcomes. [Extracted from the article] |
